Navigation Links
Rejuvasun(TM) With Omnilux(TM): Industry First to Feature FDA-Cleared, Clinically Proven Light Therapy Technology
Date:4/10/2008

nted photodynamic therapy technology, the Paterson Lamp. Originating from the University of Manchester Institute of Science and Technology and years of research, the technology was launched commercially in 1998 as Omnilux. For more, visit http://www.phototherapeutics.com.

Contact:

Duane Brodt

Coles Marketing Communications

317.571.0051

duane.brodt@colesmarketing.com


'/>"/>
SOURCE ETS Tan LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Stopping a cancer trial early: is it for the benefit of patients or industry?
2. Early-stage Commercialization Success: Pharma Companies Adjust Resources in Light of Industry Changes
3. Answers On Demand (AOD) and Vocollect Healthcare Systems Announce a First in the Industry Strategic Partnership
4. Conning Research: Long Term Care Insurance Industry Continues to Search for Broader Market
5. Uncover Best Measures for Ensuring Brand Safety in the Pharma Industry
6. The Toy Industry Association Responds to Washington State Law Governing the Sale of Toys and the Governors Veto of Key Sections of the Bill
7. IHPM and HealthMedia Announce Industrys First Behavioral Health Workplace Center for Employers
8. Retail Industry Leaders Association Files Amicus in California Health Care Litigation
9. Next Months HR in Healthcare(TM) Conference Promises to be Educational Destination for the Healthcare Industrys Senior HR Practitioners
10. Honeywell Expands Aclar(R) Production for Pharmaceutical Industry
11. Video: TI unveils industrys first family of complete analog front ends for superior ultrasound systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...ert Pathologists Discuss the Latest Developments i...RTHFIELD, Ill., Sept. 5 /PRNewswire-USNewswire/ --...point. Molecular testing and the promise,of person...reated. Digital,slides and other imaging technolog...lege of American Pathologists is taking a leadersh...
(Date:9/5/2008)...hers explain how theoretical ,anti-cloak, could br...pt. 5 (HealthDay News) -- Just in case someone dev...cientists say they know how to uncloak the objects... Optics Express , certain materials underneath an ...o be seen again. , Researchers at Shanghai Jiao...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- Speake...y in support of the aims of the "Stand,Up to Cance... "There is not a person in our country who has no...r kills 565,000 Americans annually, and each,year ...ricans must work,together to make eradicating the ...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- U.S. c...r relief to Cuban victims of Hurricane,Gustav, whi...s., (http://www.PanAmericanRelief.org ), "Donatio...perately need,after this natural disaster," says M... Initiative at the Pan American Development Founda...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:Cuban Disaster Relief Donations Sought in the Wake of Hurricane Gustav 2
...industrialised nations summit, which begins on Sat...obal health issues high on its list// of priority....h officer, addressing the press stated that the G8...hat would establish the basic guidelines for comba...
...ds Agency (FSA) has said that one in five take-out...ews for over 1.3 million Britons// who thrive on t...oncern since many fast-food restaurants were found...properly before packing the food. Also infestation...
...k, all of two years, found his eyelids stuck toget...his eye, instead of using it to treat a head// inj...ye Infirmary where he was administered treatment. ...some improvement, though a major portion of the ey...
... about the inherent risks involved in the consumpt...e human milk is capable of causing food poisoning ...ces that the human milk carries remnants of drugs ...when consumed. Even unhygienic storage of milk, an...
Other Medicine News:
(Date:9/4/2008)...ouncements Remain on Schedule with Two Abstracts A...ata Release in November 2008, BRIDGEWATER, N.J., ...Inc., a specialty pharmaceutical company focused o...sease, today announced the appointment of,Peter L....rs., Peter Garrambone,s career includes more than...
(Date:9/3/2008)..., China, Sept. 3 /- Simcere...ufacturer and supplier of,branded generic pharmace...er biotech product Endu (also known as Endostar) i...se IV clinical study., At the request of the SFDA...urther validate the safety and therapeutic efficac...
(Date:9/3/2008)...September is National Vascular Disease Awareness M...-- Diffusion Pharmaceuticals,LLC, a clinical-stage...s,for the treatment of unmet medical needs, announ...a Phase I/II clinical trial of its lead drug,candi...signated NCT00725881,on the clinicaltrials.gov Web...
(Date:9/3/2008)...ysis showed that Multaq(R) (dronedarone) decreased...fibrillation or atrial flutter already ...RIDGEWATER, N.J., Sept. 3 /...rom the ATHENA study were presented today at,the c...ty of Cardiology,congress 2008, in Munich, Germany...
Breaking Medicine Technology:Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5The HealthCentral Network Adds Skin Care Site to Its Web Properties 7104 1The HealthCentral Network Adds Skin Care Site to Its Web Properties 7104 2NanoLogix Inc Files Multiple International Patent Applications for BioNanoChannel 28TM 29 and Hydrogen Bioreactor Technology 7100 1NanoLogix Inc Files Multiple International Patent Applications for BioNanoChannel 28TM 29 and Hydrogen Bioreactor Technology 7100 2MetaCure 28TM 29 Launches Investigational Study of Gastric Stimulator for Patients With Type 2 Diabetes Who are Overweight 7096 1MetaCure 28TM 29 Launches Investigational Study of Gastric Stimulator for Patients With Type 2 Diabetes Who are Overweight 7096 2Pneumococcal conjugate vaccines can improve the lives of HIV infected children 7092 1Pneumococcal conjugate vaccines can improve the lives of HIV infected children 7092 2
... March 27, 2007--A new study shows that as rates,o...of,cardiovascular disease (CVD) linked to diabetes...e need for increased efforts to,prevent diabetes a...ors among those with diabetes, according to the in...t Study, a program of the,National Heart, Lung, an...
...sults for the year ended 31 December 2006 , Produc...e Phase,III study International partnering process..., March 28, 2007 - CeNeS Pharmaceuticals,plc ("CeN...specialty pharmaceutical company, today announces ...mber 2006. , Operational Highlights , Clinical pip...
Other Medicine Technology:Increasing Proportion of Cardiovascular Disease Due to Diabetes,Over the Last 50 Years 2Increasing Proportion of Cardiovascular Disease Due to Diabetes,Over the Last 50 Years 3CeNeS Pharmaceuticals Plc Announces Preliminary Results for The,Year Ending 31 December 2006 2CeNeS Pharmaceuticals Plc Announces Preliminary Results for The,Year Ending 31 December 2006 3
Used as a percutaneous entry needle to introduce wire guides. The coaxial design reduces potential A.V. malformations. Supplied sterile in peel-open packages. Intended for one-time use.
Used for stone manipulation and removal in the urinary tract. Enhanced wire strength permits the basket to expand the ureter more readily than standard flat-wire designs. The Unidex handle facilitate
...d for stone manipulation and removal in the urinar... to retain its shape following extreme torsion. Th...ture by allowing the basket to open at the base of...ign reduces the likelihood of mucosal damage and p...
Used to establish and maintain nephrostomy drainage following pyeloplasty. Supplied sterile in peel-open packages. Intended for one-time use. CAUTION: Periodic evaluation is advised; stent must not r
Medicine Products: